Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Bruker’s ultrafleXtreme™ MALDI-TOF/TOF to be Coupled with Nextval’s MassInsight™ Technology

Published: Monday, February 11, 2013
Last Updated: Monday, February 11, 2013
Bookmark and Share
Collaboration between Bruker and Nextval for high-throughput screening of drugs.

Bruker has announced a collaboration between Bruker and Nextval for high-throughput screening of drugs and their metabolites using Bruker's ultrafleXtreme MALDI-TOF/TOF in conjunction with Nextval's MassInsight technology.

The ultrafleXtreme mass spectrometer combines the acquisition speed of its 2 kHz smartbeam II™ laser with its Perpetual Ion Source for unrivalled productivity, ensuring optimum performance for low concentration high-throughput screening.

The versatility of Bruker's Compass™ software allows integration with Nextval's screening technology to maximize sample density and reduce sample analysis costs.

Nextval's MassInsight screening technology is based on novel surface chemistries coupled with unique microarray acoustic deposition methods (EDC Biosystems & BioSero LLC) that address critical needs in several industries including the pharmaceutical, testing and industrial markets.

Dr. Matthew Greving, CSO of Nextval, stated: "The ultrafleXtreme is an invaluable tool for Nextval because it combines the sensitivity and throughput needed for our MassInsight customers, enabling fast accurate screening of potential drug candidates and enzyme activity."

Nextval recently has been awarded a Phase II SBIR grant to further develop and commercialize their MassInsight technology for high-throughput enzyme assays.

Dr. Paul Speir, Senior Vice President of Bruker Daltonics stated: "We are excited by the combination of Nextval's MassInsight technology with the information rich, high throughput capabilities provided by the ultrafleXtreme. Moreover, we are pleased to support Nextval in their efforts to develop this important technology for the rapid and economical screening of drug candidates."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Bruker Awarded Fourth PeakForce Tapping Patent
AFM mode uniquely combines highest resolution imaging and material property mapping.
Thursday, July 24, 2014
Novel Approach for Inborn Errors of Metabolism Screening by NMR
Clinical IEM-by-NMR screening study in Turkey measures 65 metabolites in urine simultaneously, including 20 endogeneous metabolites and 45 metabolites associated with inborn errors of metabolism.
Wednesday, September 04, 2013
Bruker and SAT Announce Joint Publication
Publication of study on SISCAPA-MALDI-TOF mass spectrometry for biomarker validation and clinical research.
Monday, April 23, 2012
Bruker Celebrates Double Award Win at Pittcon 2012
The new GC-MS platform from Bruker Chemical and Applied Markets (CAM) Division – SCION TQ™ – picked up two prestigious awards at last week’s Pittcon in Orlando, Florida.
Tuesday, March 20, 2012
Scientific News
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
One Step Closer to Precision Medicine for Chronic Lung Disease Sufferers
A study led by University of North Carolina at Chapel Hill, and National Jewish Health, has provided evidence of links between SNPs and known COPD blood protein biomarkers.
Charles River Acquires Agilux
Enhances Charles River’s early-stage capabilities in bioanalytical services.
Identified Compound Stops Cells Making Ribosomes
From study in yeast, researchers have identifed a compound that interferes with the assembly of ribosomes.
CES Score May Predict Response to Cancer Treatment
Researchers identify new type of biomarker that helps predict prognosis and response to several types of cancer treatment.
Treating Sepsis with Marine Mitochondria
Mitochondrial alternative oxidase from a marine animal combats bacterial sepsis.
New Therapeutic Target for Crohn’s Disease
A promising new target for drugs that treat IBD has been identified along with a possible biomarker for IBD severity.
Analysing 10,000 Cells Simultaneously
New techniquethat traps 10,000 cells on a single chip has potential for cancer screening for individuals.
Researchers Find Fungus-Fighting Compound
A compound has been identifed that blocks growth of a fungus responsible for lung infections and allergic reactions.
Peer Reviewed Study Demonstrates Mass Spec Technique
The peer reviewed study demonstrates MS workflow, TMTCalibrator workflow, which dramatically enhances detection of key early stage Alzheimer’s biomarkers.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!